<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Luigi Di Biase, MD, PhD, FHRS, FACC
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Edward P Walsh, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Samuel Lévy, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bradley P Knight, MD, FACC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 29, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Conduction from the atria to the ventricles normally occurs via the atrioventricular node (AV)-His-Purkinje system. Patients with a preexcitation syndrome have an additional pathway, known as an accessory pathway, which directly connects the atria and ventricles, bypassing the AV node. Normal conduction through the AV node is slower than conduction over the accessory pathway. Thus, when there is conduction over an accessory pathway, the ventricles are activated earlier than if the impulse had traveled through the AV node. This early activation, referred to as
         <strong>
          preexcitation
         </strong>
         , is responsible for the classic electrocardiographic (ECG) findings of a shortened PR interval and, in most patients, a delta wave  (
         <a class="graphic graphic_waveform graphicRef67181" href="/z/d/graphic/67181.html" rel="external">
          waveform 1
         </a>
         ).
        </p>
        <p>
         Symptoms, ranging from mild palpitations to syncope and, rarely, even sudden cardiac death, are the result of tachycardia, usually due to a macroreentrant circuit involving the AV node, the ventricles, the accessory pathway, and the atria. This classic supraventricular tachycardia associated with WPW syndrome is called AV reentrant or reciprocating tachycardia (AVRT). However, preexcited atrial fibrillation (AF) or atrial flutter with a rapid ventricular response may also result in symptoms. Fortunately, the incidence of sudden death in patients with the WPW syndrome is quite low, ranging from 0 to 0.39 percent annually in several large case series, with the lowest risk seen in asymptomatic patients.
        </p>
        <p>
         Patients with the WPW syndrome are usually treated because of symptomatic arrhythmias. Treatment may sometimes be extended to asymptomatic patients with a WPW pattern if certain "high-risk" features are present. However, most asymptomatic patients with the WPW electrocardiographic pattern are not treated. Treatment options for persons with arrhythmias and the WPW syndrome include nonpharmacologic therapies (ie, catheter ablation of the accessory pathway) as well as pharmacologic therapy (to slow ventricular heart rates or to prevent arrhythmias). The choice of the optimal therapy depends on the acuity of the arrhythmia(s) and the risk of sudden cardiac death, with pharmacologic agents being the treatment of choice for most acute arrhythmias, while catheter ablation is nearly always preferred for the long-term prevention of recurrent arrhythmias involving the accessory pathway.
        </p>
        <p>
         This topic will review the available therapeutic options for the treatment of arrhythmias in the WPW syndrome. The clinical manifestations, approach to diagnosis, and the types of arrhythmias which can occur in persons with an accessory pathway and the WPW pattern are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/962.html" rel="external">
          "Wolff-Parkinson-White syndrome: Anatomy, epidemiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/976.html" rel="external">
          "Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9925775">
         <span class="h1">
          ACUTE TREATMENT OF SYMPTOMATIC ARRHYTHMIAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         While the preferred long-term treatment approach for patients with an accessory pathway, preexcitation, and symptomatic arrhythmias is catheter-based radiofrequency ablation, patients who present with an acute arrhythmia often require initial pharmacologic therapy for ventricular rate control or restoration of sinus rhythm. However, because of the electrophysiologic differences between AV nodal tissue and tissue comprising an accessory pathway, standard therapy for heart rate control may actually worsen symptoms and lead to clinical deterioration in patients with a tachycardia involving an accessory pathway. Knowledge of the presence of an accessory pathway is critical in choosing the correct initial pharmacologic therapy. (See
         <a class="local">
          'Treatment to prevent recurrent arrhythmias'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/936.html" rel="external">
          "Overview of the acute management of tachyarrhythmias"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5219027">
         <span class="h2">
          Initial assessment of hemodynamic stability
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with any patient presenting with a symptomatic tachyarrhythmia, patients with a tachycardia suspected to involve an accessory pathway should undergo an initial assessment of hemodynamic status. Patients who are hemodynamically stable can be evaluated and treated according to the type of suspected arrhythmia.
        </p>
        <p>
         However, patients with hemodynamic instability or compromise related to an ongoing tachycardia should undergo urgent electrical cardioversion [
         <a href="#rid1">
          1,2
         </a>
         ]. The technique for urgent electrical cardioversion is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/983.html" rel="external">
          "Cardioversion for specific arrhythmias"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Orthodromic AVRT
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with orthodromic atrioventricular reciprocating tachycardia (AVRT), antegrade conduction occurs via the AV node with retrograde conduction via an accessory pathway. In such patients, antegrade conduction across the AV node is typically the "weak link" of the reentrant circuit. Thus, the approach to patients with orthodromic AVRT is similar to patients with other types of paroxysmal supraventricular tachycardia, where relatively specific therapies that lengthen AV nodal refractoriness and depress its conduction can block the impulse within the AV node and terminate and prevent the tachycardia. (See
         <a class="medical medical_review" href="/z/d/html/976.html" rel="external">
          "Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway", section on 'Narrow complex AVRT'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/936.html" rel="external">
          "Overview of the acute management of tachyarrhythmias", section on 'Regular narrow QRS complex tachyarrhythmias'
         </a>
         .)
        </p>
        <p>
         We employ a step-wise approach to termination of orthodromic AVRT  (
         <a class="graphic graphic_table graphicRef62762" href="/z/d/graphic/62762.html" rel="external">
          table 1
         </a>
         ). We recommend initial treatment of acute symptomatic orthodromic AVRT with one or more vagal maneuvers (such as the Valsalva maneuver and carotid sinus massage) [
         <a href="#rid1">
          1,2
         </a>
         ]. These may be sufficient to cause AV node block and tachycardia termination in many patients [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1034.html" rel="external">
          "Vagal maneuvers"
         </a>
         .)
        </p>
        <p>
         If vagal maneuvers are ineffective, pharmacologic therapy with an AV nodal blocking agent (ie,
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         , beta blockers) should be instituted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest intravenous
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         rather than intravenous
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         as the initial choice based on its efficacy and short half-life. Intravenous adenosine is effective for acute termination of orthodromic AVRT in 80 to 90 percent of patients [
         <a href="#rid4">
          4-6
         </a>
         ]. Its ultrashort duration of action makes it a preferred agent before resorting to emergent DC cardioversion in the patient whose hemodynamic state is more tenuous.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The protocol for intravenous
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         administration is described in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef141417" href="/z/d/graphic/141417.html" rel="external">
          algorithm 1
         </a>
         ). Prior to adenosine administration, the patient should be advised of the possibility of feeling lightheaded, dizzy, or near syncopal during the injection. On rare occasions, adenosine has been reported to transiently increase atrial vulnerability to AF, a potentially serious proarrhythmic effect, and cause atrial ectopy that can reinitiate orthodromic AVRT after acute tachycardia termination [
         <a href="#rid4">
          4,7-9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         is ineffective, we proceed with intravenous
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         as the second line agent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravenous
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         , given as 5 mg boluses in a full-grown patient (0.1 mg/kg in children to a maximum dose of 5 mg; contraindicated in children less than 12 months of age) every two to three minutes (up to a cumulative initial dose of up to 15 mg), is as effective as
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         for acutely terminating orthodromic AVRT, provided that the patient is not profoundly hypotensive or suffering from heart failure associated with severely depressed ventricular systolic function rather than the rapid heart rate  (
         <a class="graphic graphic_table graphicRef62762" href="/z/d/graphic/62762.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid10">
          10,11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/951.html" rel="external">
          "Calcium channel blockers in the treatment of cardiac arrhythmias"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         If vagal maneuvers,
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         are all ineffective in terminating orthodromic AVRT, therapeutic options include use of intravenous
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         or use of a beta blocker approved for intravenous administration (
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         , and
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         )  (
         <a class="graphic graphic_table graphicRef62762" href="/z/d/graphic/62762.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid12">
          12-14
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          Procainamide
         </a>
         slows conduction and prolongs refractoriness in atrial and ventricular myocardium, accessory pathways, and the His-Purkinje system, while having no effect or causing slight shortening of AV nodal refractory period [
         <a href="#rid15">
          15,16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An approach to
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         infusion in adults is described in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef141920" href="/z/d/graphic/141920.html" rel="external">
          algorithm 2
         </a>
         ). For young children, the dose for procainamide is a bolus given over 15 to 30 minutes (7 to 10 mg/kg bolus for infants &lt;12 months of age compared with 10 to 15 mg/kg bolus for children older than 12 months), followed by an infusion of 20 to 50 micrograms/kg/minute.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          Procainamide
         </a>
         is the preferred drug if the orthodromic AVRT presents as a wide QRS complex tachycardia due to functional or preexisting chronic bundle branch block or if the diagnosis of orthodromic AVRT is in doubt. (See
         <a class="medical medical_review" href="/z/d/html/101641.html" rel="external">
          "Wide QRS complex tachycardias: Approach to management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          Metoprolol
         </a>
         – 2.5 to 5 mg IV bolus over two to five minutes; if no response, an additional 2.5 to 5 mg IV bolus may be administered every 10 minutes to a total dose of 15 mg.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13208282">
         <span class="h3">
          Permanent junctional reciprocating tachycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Permanent junctional reciprocating tachycardia (PJRT) is a persistent tachycardia (with a long RP interval on the surface electrocardiogram) that most often occurs in early childhood and is usually caused by a rare type of orthodromic AVRT involving a slowly conducting concealed accessory pathway, which is usually posteroseptal in location. As implied by the name, PJRT is incessant. (See
         <a class="medical medical_review" href="/z/d/html/976.html" rel="external">
          "Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway", section on 'Permanent junctional reciprocating tachycardia'
         </a>
         .)
        </p>
        <p>
         Ablation of the accessory pathway is the preferred treatment for PJRT caused by a slowly conducting accessory pathway since this arrhythmia is often refractory to medical therapy. In a cohort of 194 patients (median age at diagnosis 3.2 months, 57 percent less than one year of age) from 11 institutions treated for PJRT between 2000 and 2010, initial medical management (attempted in 76 percent of patients) led to complete control of the arrhythmia in only 23 percent of patients [
         <a href="#rid17">
          17
         </a>
         ]. An additional 47 percent of patients had clinical improvement with slower and/or less sustained tachycardia, but perfect pharmacologic control is less common.
        </p>
        <p>
         However, in patients presenting with acute symptomatic PJRT, the choice of initial medical therapy is similar to conventional orthodromic AVRT [
         <a href="#rid18">
          18
         </a>
         ].
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          Adenosine
         </a>
         and
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         can be tried but usually only interrupt PJRT for a few beats. Intravenous
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef141920" href="/z/d/graphic/141920.html" rel="external">
          algorithm 2
         </a>
         ) will occasionally result in a longer-lasting interruption of PJRT, but it rarely results in perfect control. As a temporizing measure prior to ablation, effective medical control of PJRT can often be achieved with oral
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         . (See
         <a class="local">
          'Orthodromic AVRT'
         </a>
         above and
         <a class="local">
          'Catheter ablation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Antidromic AVRT
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with antidromic atrioventricular reciprocating tachycardia (AVRT), antegrade conduction occurs via the accessory pathway with retrograde conduction usually via the AV node (or sometimes via a second accessory pathway if multiple pathways are present). The following recommendations apply to patients with hemodynamically antidromic AVRT [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          If suspected AVRT is strictly regular and monomorphic
         </strong>
         – If the tachycardia is strictly regular and monomorphic, a trial of a short-acting AV node-specific blocking drug such as
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef141417" href="/z/d/graphic/141417.html" rel="external">
          algorithm 1
         </a>
         ) can be attempted. Even though retrograde AV node conduction may be a "weak link" during antidromic AVRT, in the acute setting it is difficult to exclude the possibility of a second accessory pathway as the retrograde limb without formal electrophysiologic testing, so AV node blocking therapy should be undertaken cautiously.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Failure to convert the tachycardia should make one suspicious of a second accessory pathway participating in the circuit, at which point an alternate agent such as
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef141920" href="/z/d/graphic/141920.html" rel="external">
          algorithm 2
         </a>
         ) or
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         should be considered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          For most suspected or known AVRT
         </strong>
         – Practically speaking, verification of an antidromic AVRT is difficult outside the electrophysiology laboratory, so the intravenous drug of choice for acute termination of most suspected or known antidromic AVRT is
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef141920" href="/z/d/graphic/141920.html" rel="external">
          algorithm 2
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. Even if procainamide does not result in tachycardia termination, intravenous procainamide will usually slow the tachycardia rate and improve the hemodynamic state  (
         <a class="graphic graphic_table graphicRef62762" href="/z/d/graphic/62762.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          For undiagnosed wide complex tachycardia
         </strong>
         – If the diagnosis is not certain, the patient should be considered to have an undiagnosed wide QRS tachycardia; of particular concern is ventricular tachycardia, which can become hemodynamically unstable or even degenerate into ventricular fibrillation following administration of one of these drugs. If uncertainty ever exists about the exact tachycardia mechanism, a presumptive diagnosis of ventricular tachycardia should be made, and the patient treated accordingly. (See
         <a class="medical medical_review" href="/z/d/html/976.html" rel="external">
          "Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway", section on 'Wide complex AVRT'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/920.html" rel="external">
          "Wide QRS complex tachycardias: Approach to the diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/101641.html" rel="external">
          "Wide QRS complex tachycardias: Approach to management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Atrial fibrillation with preexcitation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with an accessory pathway capable of antegrade conduction who develop AF, conduction to the ventricle often occurs through a combination of the normal conduction pathway (via the AV node) and the accessory pathway. However, because most accessory pathways have a shorter refractory period than the AV node, the ventricular rate can be more rapid if AV conduction occurs preferentially via the accessory pathway. As such, AV nodal blocking drugs (
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         , beta blockers, and
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         ) should be
         <strong>
          avoided
         </strong>
         in patients with preexcited AF since blocking the AV node will promote conduction down the accessory pathway and may sometimes directly enhance the rate of conduction over the accessory pathway. (See
         <a class="local">
          'When to avoid AV nodal blockers'
         </a>
         below.)
        </p>
        <p>
         The goals of acute drug therapy for preexcited AF are prompt control of the ventricular response and, ideally, termination of AF. If the patient is unstable because of a rapid ventricular response, electrical cardioversion should be performed. For more stable patients, trials of intravenous medications can be performed cautiously. Treatment of preexcited AF requires a parenteral drug with rapid onset of action that lengthens antegrade refractoriness and slows conduction in both the AV node/His-Purkinje system and the accessory pathway.
        </p>
        <p>
         The following is our approach to the acute treatment of patients with preexcited AF, which is consistent with published professional society guidelines [
         <a href="#rid1">
          1,2,19
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who are hemodynamically unstable, we recommend urgent electrical cardioversion [
         <a href="#rid1">
          1,2,19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/983.html" rel="external">
          "Cardioversion for specific arrhythmias", section on 'External cardioversion/defibrillation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who are hemodynamically stable, we suggest initial medical therapy for rhythm control versus rate control. This is based on the greater ease of controlling the ventricular rate in sinus rhythm. While there is no clear first-line medication for rhythm control, options include
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         and
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intravenous
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef141920" href="/z/d/graphic/141920.html" rel="external">
          algorithm 2
         </a>
         ) is effective for acute therapy of preexcited AF because of its effects on atrial and ventricular myocardium without any AV nodal blocking effect. Because of its effect on atrial myocardium, procainamide may terminate AF; however, if AF persists, the ventricular rate usually slows due to effects on refractoriness and conduction in the accessory pathway. The pediatric experience with
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         is very limited, so procainamide is usually the preferred intravenous drug option for preexcited AF in the younger population.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Even if
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         does not result in tachycardia termination, intravenous procainamide will usually slow the tachycardia rate and improve the hemodynamic state  (
         <a class="graphic graphic_table graphicRef62762" href="/z/d/graphic/62762.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef141920" href="/z/d/graphic/141920.html" rel="external">
          algorithm 2
         </a>
         ). This is often followed by an infusion of 1 to 4 mg/minute.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For young children, the dose for
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         is a bolus given over 15 to 30 minutes (7 to 10 mg/kg bolus for infants &lt;12 months of age compared with 10 to 15 mg/kg bolus for children older than 12 months), followed by an infusion of 20 to 50 micrograms/kg/minute.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          Ibutilide
         </a>
         , a class III antiarrhythmic drug that prolongs the refractoriness of the AV node, His-Purkinje system, and accessory pathway, is useful for acute termination of AF and atrial flutter. In one series of 22 patients with WPW and AF during an electrophysiologic study, ibutilide prolonged the shortest preexcited RR interval and terminated the arrhythmia in 95 percent [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/924.html" rel="external">
          "Therapeutic use of ibutilide"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For all patients with preexcited AF, we recommend
         <strong>
          not
         </strong>
         using standard AV nodal blocking medications (ie, beta blockers, non-dihydropyridine calcium channel blockers [
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         and
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         ],
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ). Blocking the AV node may result in increased conduction of atrial impulses to the ventricle by way of the accessory pathway, increasing the ventricular rate and potentially resulting in hemodynamic instability. (See
         <a class="local">
          'When to avoid AV nodal blockers'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         The class IC antiarrhythmic drugs
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         and
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         and the class III agent
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         are effective when used in this setting, but the parenteral formulations of these drugs are not approved for use in some countries, including the United States [
         <a href="#rid21">
          21-24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          When to avoid AV nodal blockers
         </span>
         <span class="headingEndMark">
          —
         </span>
         AV node-specific antiarrhythmic drugs that are normally used to control the ventricular rate during AF are
         <strong>
          contraindicated
         </strong>
         (
         <a class="graphic graphic_table graphicRef62762" href="/z/d/graphic/62762.html" rel="external">
          table 1
         </a>
         ) for patients with preexcited AF:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          Verapamil
         </a>
         is perhaps the
         <strong>
          most dangerous
         </strong>
         AV nodal blocker to administer to patients with preexcited AF [
         <a href="#rid25">
          25-27
         </a>
         ]. Intravenous verapamil lengthens AV node refractoriness, decreases concealed conduction into the accessory pathway, and has no direct effect on the accessory pathway. Myocardial contractility and systemic vascular resistance are also reduced; these effects may cause a reflex increase in already elevated sympathetic tone that further shortens accessory pathway refractoriness. Precipitation of cardiac arrest by degeneration of preexcited AF to ventricular fibrillation has been reported after intravenous verapamil administration [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          Adenosine
         </a>
         causes an effect similar to
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         and also can precipitate ventricular fibrillation. Adenosine will not convert AF and has only a transient effect on the AV node. Its use is
         <strong>
          contraindicated
         </strong>
         in AF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beta blockers, when used alone, do not increase accessory pathway refractoriness. Additionally, inhibition of AV node conduction may enhance the preexcited ventricular rate response by decreasing the degree of concealed retrograde conduction into the accessory pathway. An accessory pathway with a short intrinsic antegrade refractory period that was initially competing with the AV node could then become the dominant route for rapid, antegrade conduction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         , which may slow conduction in an accessory pathway during chronic oral administration, is not known to slow accessory pathway conduction with acute IV administration [
         <a href="#rid28">
          28,29
         </a>
         ]. Because amiodarone also has beta blocking properties, it may increase conduction via the accessory pathway, leading to a faster ventricular rate and the potential for ventricular fibrillation [
         <a href="#rid19">
          19
         </a>
         ]. Amiodarone should generally not be used in patients with AF and accessory pathway.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          Digoxin
         </a>
         is also contraindicated because of blockade of AV nodal conduction and its unpredictable effect on accessory pathway refractoriness [
         <a href="#rid30">
          30
         </a>
         ]. The vagomimetic action of digoxin lengthens AV node refractoriness and reduces concealed retrograde conduction into the accessory pathway.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H25777324">
         <span class="h1">
          TREATMENT TO PREVENT RECURRENT ARRHYTHMIAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once patients with the Wolff-Parkinson-White syndrome have been stabilized following an acute episode of symptomatic tachyarrhythmia, patients should be evaluated for additional therapy aimed at preventing recurrent symptomatic arrhythmias. The preferred long-term treatment approach for nearly all patients with an accessory pathway, preexcitation, and a symptomatic arrhythmia is catheter ablation of the accessory pathway. However, for patients who are not candidates for ablation procedures, or for very select patients with rare, well-tolerated arrhythmias, antiarrhythmic therapy is an alternative. When antiarrhythmic drugs are used, the choice of agent is determined by the etiology of the arrhythmia and its electrophysiologic properties  (
         <a class="graphic graphic_table graphicRef62762" href="/z/d/graphic/62762.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H13211133">
         <span class="h2">
          Catheter ablation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with an accessory pathway and symptomatic arrhythmias including orthodromic AVRT, antidromic AVRT, and preexcited AF or atrial flutter, we recommend catheter ablation rather than pharmacologic therapy [
         <a href="#rid1">
          1
         </a>
         ]. Initial case-series demonstrated both the safety and efficacy of this approach, data which have been replicated in numerous studies [
         <a href="#rid31">
          31-37
         </a>
         ]. The standard energy source used to ablate accessory pathways is radiofrequency current, although cryoenergy can be used as an alternative to radiofrequency energy to ablate accessory pathways that are in close proximity to the AV node or bundle of His [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1007.html" rel="external">
          "Overview of catheter ablation of cardiac arrhythmias"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13209477">
         <span class="h3">
          Indications for ablation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with an accessory pathway are candidates for ablation in the following settings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptomatic tachyarrhythmias.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Occupations in which the development of symptoms would put themselves or others at risk (eg, truck drivers or airline pilots, some athletes).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Selected asymptomatic patients. (See
         <a class="local">
          'Asymptomatic patients'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13209491">
         <span class="h4">
          Symptomatic patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptom control is the most common indication for ablation. The 2015 ACC/AHA/HRS guidelines on the management of supraventricular arrhythmias recommended catheter ablation as a first-line therapy for patients who have had symptomatic AVRT or preexcited AF [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13209498">
         <span class="h4">
          Asymptomatic patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal approach is controversial in asymptomatic patients who are coincidentally found to have evidence of an accessory pathway on an ECG (ie, WPW pattern) [
         <a href="#rid39">
          39-41
         </a>
         ]. The risk of sudden cardiac death (SCD) is low, and the risk of developing symptoms also appears to be low, although a wide range of incidences have been reported [
         <a href="#rid42">
          42,43
         </a>
         ]. Among those with a WPW ECG pattern, the likelihood of developing symptoms varies with age. Children are at the highest risk, while those who remain asymptomatic over age 35 years are unlikely to develop symptoms [
         <a href="#rid40">
          40
         </a>
         ]. In a prospective study of 550 asymptomatic patients with WPW ECG pattern who were followed for a median of 22 months, 13 patients (2.4 percent) developed ventricular fibrillation (VF) [
         <a href="#rid44">
          44
         </a>
         ], most of whom (11 of 13) were children. Fortunately, all of the patients developed warning symptoms (usually presyncope or dizziness) and sought medical attention, and none died from the VF episode.
        </p>
        <p>
         The 2015 ACC/AHA/HRS guidelines state that observation of patients with WPW pattern alone is reasonable; however, the guidelines also state that catheter ablation is reasonable in asymptomatic patients [
         <a href="#rid1">
          1
         </a>
         ]. Additionally, in a 2012 consensus statement on the management of asymptomatic young patients with the WPW pattern, ablation is recommended for patients felt to be at higher risk of SCD based on the results of electrophysiologic testing [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/962.html" rel="external">
          "Wolff-Parkinson-White syndrome: Anatomy, epidemiology, clinical manifestations, and diagnosis", section on 'Electrophysiology studies (EPS)'
         </a>
         .)
        </p>
        <p>
         For most asymptomatic patients with preexcitation, particularly those over age 35 to 40 years, we suggest observation. However, in some asymptomatic patients, particularly children, who are felt to be at higher risk of an arrhythmia or SCD, we suggest risk stratification to identify individuals who may benefit from treatment  (
         <a class="graphic graphic_algorithm graphicRef119379" href="/z/d/graphic/119379.html" rel="external">
          algorithm 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2850579">
         <span class="h3">
          Localizing the accessory pathway
         </span>
         <span class="headingEndMark">
          —
         </span>
         The location of most accessory pathways can be estimated using the preexcitation pattern on the surface electrocardiogram. However, more precise localization of the accessory pathway during catheter-based mapping prior to catheter ablation utilizes several parameters [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To determine the atrial insertion site, the earliest site of retrograde atrial activation during orthodromic atrioventricular (AV) reciprocating tachycardia (AVRT) or ventricular pacing must be identified [
         <a href="#rid46">
          46,47
         </a>
         ]. The assumption is that the local retrograde ventriculoatrial (VA) interval on the recording electrode will be shortest at the atrial insertion site. Compared with pacing at sites more remote from the accessory pathway, atrial pacing near the atrial insertion of the accessory pathway will create a greater degree of preexcitation with a shorter delay between the stimulus and the onset of the delta wave [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         More precise localization of the ventricular insertion site is obtained by mapping along the AV groove in sinus rhythm to determine the site of earliest ventricular activation during preexcited beats. Local ventricular activation at the ventricular insertion site frequently precedes the onset of the delta wave on the surface ECG by 10 to 40 milliseconds  (
         <a class="graphic graphic_waveform graphicRef72398" href="/z/d/graphic/72398.html" rel="external">
          waveform 2
         </a>
         ) [
         <a href="#rid49">
          49,50
         </a>
         ]. If preexcitation is minimal in sinus rhythm, then atrial pacing can be performed to facilitate ventricular preexcitation by delaying AV nodal conduction.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13209519">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The acute success rate with catheter-based ablation is approximately 85 to 95 percent but can approach 100 percent depending upon the location of the accessory pathway and the precision of pathway localization [
         <a href="#rid34">
          34-37,44
         </a>
         ]. Success rates are lower (84 to 89 percent) for septal accessory pathways  (
         <a class="graphic graphic_waveform graphicRef51546" href="/z/d/graphic/51546.html" rel="external">
          waveform 3
         </a>
         and
         <a class="graphic graphic_waveform graphicRef78363" href="/z/d/graphic/78363.html" rel="external">
          waveform 4
         </a>
         ) [
         <a href="#rid31">
          31,32,35,36,51-55
         </a>
         ]. Additionally, long-term success rates may be closer to 80 percent at five years post-ablation [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         As examples of the efficacy of ablation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis that included data from 64 studies, including 3495 patients undergoing radiofrequency catheter ablation (RFA) and 749 patients undergoing cryoablation of septal accessory pathways, acute procedural success was similar with either approach (89 versus 86 percent with RFA versus cryoablation, respectively) [
         <a href="#rid55">
          55
         </a>
         ]. Long-term success rates were higher with RFA (88 versus 76 percent with cryoablation), although cryoablation resulted in lower risk of persistent AV block (0 versus 3 percent with RFA).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 519 patients from a single, large volume center who underwent EP study and radiofrequency ablation of accessory pathways in the late 1990s and were followed for an average of 22 months, accessory pathway conduction was abolished in 92 percent of patients, although one or two additional ablation procedures were required in 6 percent [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a single-center, prospective observational study of 1168 patients who underwent RFA between May 2005 and May 2010 and were followed for a median of eight years, there were no episodes of ventricular fibrillation or sudden cardiac death [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In addition to location (ie, septal, lateral, etc) of the accessory pathway, the efficacy of catheter ablation can be affected by the presence of multiple accessory pathways and the depth of the accessory pathway within the myocardial (ie, epicardial versus endocardial).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple accessory pathways – Multiple accessory pathways are found in as many as 13 percent of patients with WPW syndrome. Ablation of multiple accessory pathways is possible, but it requires a longer procedure time and is associated with a higher rate of recurrence [
         <a href="#rid35">
          35,57,58
         </a>
         ]. As an example, in one study of 858 patients undergoing EP study and ablation for WPW syndrome in which multiple accessory pathways were identified in 8.5 percent of patients, procedural success was similar for single and multiple pathways, but the rate of recurrent arrhythmias over a mean follow-up of 43 months was significantly higher in persons with multiple accessory pathways (9.5 versus 2.5 percent) [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Epicardial accessory pathway location – One reason that catheter ablation may fail is with an accessory pathway that is located closer to the epicardial surface. In such patients, the usual ablation procedure via transvenous catheters at the endocardial surface may not affect the critical tissue. Although not widely done, percutaneous epicardial ablation is possible via subxiphoid access of the pericardial space. The feasibility of this approach was demonstrated in a report of 48 patients with a variety of arrhythmias (10 with WPW syndrome) who had failed endocardial ablation [
         <a href="#rid59">
          59
         </a>
         ]. Via subxiphoid instrumentation, 5 of the 10 patients had accessory pathways localized to the epicardial surface, and three were successfully ablated.
        </p>
        <p>
        </p>
        <p>
         Catheter ablation is also effective in the treatment of PJRT. From a cohort of 194 patients (median age at diagnosis 3.2 months, 57 percent less than one year of age) from 11 institutions treated for PJRT between 2000 and 2010, 140 patients underwent a total of 175 catheter ablation procedures [
         <a href="#rid17">
          17
         </a>
         ]. PJRT was successfully eliminated in 90 percent of patients, with minor complications reported in only 9 percent of patients, and no major complications.
        </p>
        <p class="headingAnchor" id="H13209526">
         <span class="h3">
          Arrhythmia recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent arrhythmias involving an accessory pathway, manifested by return of delta waves on the electrocardiogram or spontaneous paroxysmal supraventricular tachycardia, have been reported in 5 to 12 percent of patients [
         <a href="#rid36">
          36,51,52,58,60
         </a>
         ]. The recurrence rate is higher with ablation of multiple pathways or right free wall or septal accessory pathways [
         <a href="#rid53">
          53,58,60
         </a>
         ]. Approximately one-half of recurrences occur in the first 12 hours after the procedure [
         <a href="#rid60">
          60
         </a>
         ]. Repeat ablation usually leads to permanent cure in patients who experience a recurrence [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         To unmask any residual conduction via an accessory pathway prior to ending the ablation procedure, intravenous
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         can be administered to transiently block the AV node. We primarily use adenosine when there is difficulty determining if the pathway has been successfully ablated.
        </p>
        <p>
         AF can recur following accessory pathway ablation; however, the ability for AF to be preexcited with conduction via an accessory pathway should be reduced or eliminated following ablation. In a series of 91 patients with documented paroxysmal AF prior to successful ablation of an accessory pathways, 18 (20 percent) had recurrent episodes of AF at two-year follow-up, although advancing age was the only independent predictor of recurrent AF on multivariate analysis [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13209533">
         <span class="h3">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data on complication rates come from both case series and a voluntary national registry. The reported incidence of nonfatal complications is on the order of 2 to 4 percent, which is similar to rates seen with ablation procedures for other arrhythmias [
         <a href="#rid35">
          35,36,45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1007.html" rel="external">
          "Overview of catheter ablation of cardiac arrhythmias", section on 'Complications'
         </a>
         .)
        </p>
        <p>
         The incidence and nature of complications in general clinical practice was illustrated in a report from a voluntary national registry in the United States of 3357 patients undergoing EP study and ablation for a variety of indications [
         <a href="#rid36">
          36
         </a>
         ]. Among the 654 patients treated for WPW syndrome, major procedural complications occurred in 2 percent, most commonly cardiac tamponade.
        </p>
        <p>
         Specific complications may occur that are related to the anatomic site of ablation, including complete AV block resulting from ablation of a septal accessory pathway near the AV node, acute interatrial shunting related to transseptal catheterization for ablation of left-sided accessory pathways (although there are usually no adverse long-term sequelae), and inappropriate sinus tachycardia may be present following ablation of a posteroseptal accessory pathway, suggesting disruption of the parasympathetic and/or sympathetic innervation of the sinus and AV nodes [
         <a href="#rid62">
          62-68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13209540">
         <span class="h2">
          Surgical ablation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to the advent of catheter-mediated radiofrequency ablation, surgical ablation of accessory pathways was the standard technique in patients with drug-refractory WPW syndrome. The long-term success rate for WPW surgery is now almost 100 percent with an operative mortality rate of less than 1 percent [
         <a href="#rid69">
          69-71
         </a>
         ]. Despite these excellent outcomes, catheter-mediated radiofrequency ablation has emerged as the preferred therapy for treatment of accessory pathways. However, surgical ablation remains an effective treatment strategy in patients suffering from highly symptomatic and hemodynamically unstable, drug-refractory arrhythmias in whom radiofrequency energy catheter ablation has failed, when performed at centers with a proven track record of success in performing the procedure [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13212220">
         <span class="h2">
          Medical therapy for arrhythmia prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with an accessory pathway and symptomatic arrhythmias (including orthodromic AVRT, antidromic AVRT, and preexcited AF or atrial flutter) who are not candidates for or who refuse ablation of the accessory pathway, we suggest pharmacologic therapy aimed at preventing further arrhythmias and/or slowing the ventricular response rate [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Chronic therapy with
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         or
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         should be avoided in all patients with WPW syndrome.
        </p>
        <p class="headingAnchor" id="H5219558">
         <span class="h3">
          For recurrent orthodromic AVRT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The efficacy of an antiarrhythmic drug in preventing orthodromic atrioventricular reciprocating tachycardia (AVRT) is related to its ability to alter the electrophysiologic properties of the circuit, rendering it incapable of sustaining reentry. Antiectopic activity to decrease the number of arrhythmia triggers (eg, premature atrial complex [PACs; also referred to a premature atrial beat, premature supraventricular complex, or premature supraventricular beat] and ventricular premature beats) is another desirable effect.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The class IC antiarrhythmic drugs
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         and
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         (
         <a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">
          table 2
         </a>
         ) possess the most favorable benefit/risk ratio and are the drugs of choice for prevention of recurrent orthodromic AVRT [
         <a href="#rid73">
          73-76
         </a>
         ]. An important exception is the presence of known coronary disease, a setting in which class IC drugs can increase mortality due to proarrhythmia [
         <a href="#rid77">
          77
         </a>
         ]. Both flecainide and propafenone have been approved for prevention of paroxysmal supraventricular tachyarrhythmias, including orthodromic AVRT. Propafenone has a potential advantage since it also has mild beta blocking activity [
         <a href="#rid75">
          75,76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beta blockers are still occasionally used as second-line therapy for chronic suppression of orthodromic AVRT in patients with "low-risk" WPW accessory pathways (eg, only intermittently manifest or know to have a long effective refractory period), but they are not advised for patients who have developed or may develop preexcited AF. Chronic therapy with
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         or
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         should be avoided in all patients with WPW syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The class IA antiarrhythmic drugs  (
         <a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">
          table 2
         </a>
         ) lengthen antegrade and retrograde refractoriness and slow conduction in the accessory pathway. However, these drugs are less potent than the class IC drugs, they only minimally lengthen AV node refractoriness, and they have a substantial risk of intolerable noncardiac adverse effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         has multiple electrophysiologic effects that make it effective in suppressing orthodromic AVRT, including beta blocking activity, class III effects to prolong action potential repolarization, blockade of the fast sodium and slow calcium inward currents, and suppression of ectopic beats [
         <a href="#rid78">
          78-80
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/926.html" rel="external">
          "Amiodarone: Clinical uses"
         </a>
         ). These effects result in slowing of impulse conduction and lengthening of refractoriness in both the bypass tract and the AV node/His-Purkinje system. However, it has a number of common adverse effects, including pulmonary, thyroid, and hepatic toxicity, which is a concern for patients with WPW who are often young and may require many years of therapy. (See
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5220010">
         <span class="h3">
          For recurrent antidromic AVRT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ablation of the accessory pathway is the preferred therapy for chronic prevention of antidromic AVRT. An important concern about long-term medical therapy of this arrhythmia is the potential for very rapid ventricular rates should AF develop, given that the accessory pathway is capable of antegrade preexcited conduction during AF. We suggest drug therapy for the prevention of recurrent antidromic AVRT only in patients who are not candidates for or who refuse ablation of the accessory pathway. (See
         <a class="local">
          'Catheter ablation'
         </a>
         above.)
        </p>
        <p>
         The selection of an effective antiarrhythmic drug should be based upon the effect of the drug on the electrophysiologic properties of the various parts of the reentrant circuit and on the ability to suppress the arrhythmia. The AV nodal blocking agents (beta blockers, calcium channel blockers, and
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         ) are
         <strong>
          contraindicated
         </strong>
         because of the possible occurrence of AF with accelerated conduction down the accessory pathway. (See
         <a class="local">
          'When to avoid AV nodal blockers'
         </a>
         above.)
        </p>
        <p>
         The class IC drugs
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         and
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         (
         <a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">
          table 2
         </a>
         ) are the agents of choice in the absence of other contraindications such as underlying structural heart disease or myocardial ischemia  (
         <a class="graphic graphic_table graphicRef62762" href="/z/d/graphic/62762.html" rel="external">
          table 1
         </a>
         ). These drugs may increase mortality in patients with known coronary disease due to proarrhythmia [
         <a href="#rid77">
          77
         </a>
         ]. Class IA drugs and
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         are also effective but are less desirable because of side effects.
        </p>
        <p class="headingAnchor" id="H2558847">
         <span class="h3">
          For recurrent preexcited atrial fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ablation of the accessory pathway is the preferred therapy for the prevention of recurrent preexcited AF. While ablation of the accessory pathway will not directly impact the development of AF, it should prevent the possibility of very rapid ventricular rates due to antegrade conduction via the accessory pathway. We suggest medical therapy for the prevention of recurrent preexcited AF only in patients who are not candidates for, or refuse, ablation of the accessory pathway. (See
         <a class="local">
          'Catheter ablation'
         </a>
         above.)
        </p>
        <p>
         The drug selected for prevention of intermittent AF in the WPW syndrome should possess antifibrillatory activity on the atrial myocardium, antiectopic activity to suppress both PACs and ventricular premature beats that can induce AF, and should prevent AVRT since the latter can subsequently degenerate into AF. The drug must also lengthen refractoriness in both the accessory pathway and the AV node and His-Purkinje system to provide adequate background protection against a rapid ventricular response should AF intermittently occur. (See
         <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants"
         </a>
         .)
        </p>
        <p>
         The class IC drugs
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         and
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         (
         <a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">
          table 2
         </a>
         ) possess the best electrophysiologic profile for achieving these goals if no cardiac contraindications exist [
         <a href="#rid81">
          81,82
         </a>
         ]. Class IA drugs are less potent and have more noncardiac adverse effects as previously noted.
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         may be useful for the prevention of recurrent AF when class IC and IA drugs are ineffective and/or not tolerated and when ablation therapy is inappropriate or has failed [
         <a href="#rid83">
          83,84
         </a>
         ]. Amiodarone should not be used in the acute management of AF. (See
         <a class="local">
          'When to avoid AV nodal blockers'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3431372042">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">
          "Society guideline links: Atrial fibrillation"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">
          "Society guideline links: Arrhythmias in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/116932.html" rel="external">
          "Society guideline links: Catheter ablation of arrhythmias"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/116931.html" rel="external">
          "Society guideline links: Supraventricular arrhythmias"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7403958">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15669.html" rel="external">
          "Patient education: Wolff-Parkinson-White syndrome (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/3424.html" rel="external">
          "Patient education: Wolff-Parkinson-White syndrome (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients requiring treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Symptomatic patients
         </strong>
         – Patients with the Wolff-Parkinson-White (WPW) syndrome with symptomatic arrhythmia are generally treated to manage the symptoms caused by the arrhythmia and reduce the risk of a life-threatening arrhythmia. (See
         <a class="local">
          'Acute treatment of symptomatic arrhythmias'
         </a>
         above and
         <a class="local">
          'Treatment to prevent recurrent arrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Asymptomatic patients
         </strong>
         – For most asymptomatic patients with preexcitation, particularly those over age 35 to 40, we suggest observation rather than ablation or pharmacotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, risk stratification is performed in certain asymptomatic patients who are felt to be at higher risk of an arrhythmia or sudden cardiac death (SCD; particularly children, individuals with congenital heart disease, and those with cardiomyopathy) to identify those who may benefit from treatment  (
         <a class="graphic graphic_algorithm graphicRef119379" href="/z/d/graphic/119379.html" rel="external">
          algorithm 3
         </a>
         ). (See
         <a class="local">
          'Asymptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment options
         </strong>
         – These include nonpharmacologic therapies (ie, catheter ablation of the accessory pathway) as well as pharmacologic therapy (to slow ventricular heart rates or to prevent arrhythmias). The choice of the optimal therapy depends on the acuity of the arrhythmia(s) and the risk of sudden cardiac death. (See
         <a class="local">
          'Acute treatment of symptomatic arrhythmias'
         </a>
         above and
         <a class="local">
          'Treatment to prevent recurrent arrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodynamic instability
         </strong>
         – All patients with any arrhythmia (ie, orthodromic atrioventricular reciprocating tachycardia [AVRT], antidromic AVRT, atrial fibrillation/flutter) involving an accessory pathway should undergo prompt initial assessment of hemodynamic status. Patients who are felt to be hemodynamically unstable related to their arrhythmia should undergo urgent electrical cardioversion. (See
         <a class="local">
          'Initial assessment of hemodynamic stability'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/983.html" rel="external">
          "Cardioversion for specific arrhythmias"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute orthodromic AVRT
         </strong>
         – For patients with acute symptomatic orthodromic AVRT who are hemodynamically stable, our approach is as follows  (
         <a class="graphic graphic_table graphicRef62762" href="/z/d/graphic/62762.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="local">
          'Orthodromic AVRT'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial therapy
         </strong>
         – We recommend initial treatment with one or more vagal maneuvers rather than pharmacologic therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pharmacologic therapy
         </strong>
         – If vagal maneuvers are ineffective, pharmacologic therapy with an AV nodal blocking agent (ie,
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         , beta blockers) should be instituted. We suggest intravenous adenosine rather than intravenous verapamil as the initial choice based on its efficacy and short half-life (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         is ineffective, we proceed with intravenous
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         as the second line agent. If orthodromic AVRT persists, intravenous
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef141920" href="/z/d/graphic/141920.html" rel="external">
          algorithm 2
         </a>
         ) and beta blockers approved for intravenous administration (eg,
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         , and
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         ) are additional therapeutic options.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute antidromic AVRT
         </strong>
         – For patients with acute symptomatic
         <strong>
          antidromic
         </strong>
         AVRT who are hemodynamically stable, we treat with intravenous
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef141920" href="/z/d/graphic/141920.html" rel="external">
          algorithm 2
         </a>
         ) in an effort to terminate the tachycardia or, if the tachycardia persists, slow the ventricular response. (See
         <a class="local">
          'Antidromic AVRT'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute atrial fibrillation
         </strong>
         – For patients with acute symptomatic preexcited atrial fibrillation (AF) who are hemodynamically stable, our approach is as follows (see
         <a class="local">
          'Atrial fibrillation with preexcitation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Recommended therapy
         </strong>
         – We suggest initial medical therapy for rhythm control versus rate control (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). This is based on the greater ease of controlling the ventricular rate in sinus rhythm. While there is no clear first-line medication for rhythm control, options include
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef141920" href="/z/d/graphic/141920.html" rel="external">
          algorithm 2
         </a>
         ) and
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Drugs to avoid
         </strong>
         – For all patients with preexcited AF, we recommend
         <strong>
          against
         </strong>
         using standard AV nodal blocking medications (ie, beta blockers, non-dihydropyridine calcium channel blockers [
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         and
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         ],
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). Blocking the AV node may result in increased conduction of atrial impulses to the ventricle by way of the accessory pathway, increasing the ventricular rate and potentially resulting in hemodynamic instability. (See
         <a class="local">
          'When to avoid AV nodal blockers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of recurrent arrhythmias
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          First-line therapy
         </strong>
         – For patients with an accessory pathway and symptomatic arrhythmias including orthodromic AVRT, antidromic AVRT, and preexcited AF or atrial flutter, we recommend catheter ablation (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). (See
         <a class="local">
          'Catheter ablation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alternate therapy
         </strong>
         – For patients with an accessory pathway and symptomatic arrhythmias (including orthodromic AVRT, antidromic AVRT, and preexcited AF or atrial flutter) who are not candidates for, or refuse, ablation of the accessory pathway, we suggest pharmacologic therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Medical therapy for arrhythmia prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For prevention of recurrent orthodromic AVRT in the absence of underlying structural heart disease, class IC antiarrhythmic drugs (eg,
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         ) are the drugs of choice, although beta blockers, class IA antiarrhythmic drugs, and
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         may also be considered.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For prevention of recurrent antidromic AVRT and preexcited AF in the absence of underlying structural heart disease, class IC antiarrhythmic drugs (eg,
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         ) are also the drugs of choice. However, the AV nodal blocking agents (beta blockers, calcium channel blockers, and
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         ) are
         <strong>
          contraindicated
         </strong>
         in these patients, so class IA antiarrhythmic drugs and
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         should be considered in patients with concurrent structural heart disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Failed catheter ablation
         </strong>
         – For patients with preexcitation and symptomatic arrhythmias or AF or atrial flutter who have failed catheter ablation of the accessory pathway, we typically perform a repeat attempt at catheter ablation or consider proceeding with surgical ablation. (See
         <a class="local">
          'Catheter ablation'
         </a>
         above and
         <a class="local">
          'Surgical ablation'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2016; 133:e506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020; 41:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker S, Cutting P. Impact of a modified Valsalva manoeuvre in the termination of paroxysmal supraventricular tachycardia. Emerg Med J 2010; 27:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belardinelli L, Linden J, Berne RM. The cardiac effects of adenosine. Prog Cardiovasc Dis 1989; 32:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           diMarco JP, Sellers TD, Lerman BB, et al. Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias. J Am Coll Cardiol 1985; 6:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiMarco JP, Sellers TD, Berne RM, et al. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation 1983; 68:1254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Exner DV, Muzyka T, Gillis AM. Proarrhythmia in patients with the Wolff-Parkinson-White syndrome after standard doses of intravenous adenosine. Ann Intern Med 1995; 122:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dougherty AH, Gilman JK, Wiggins S, et al. Provocation of atrioventricular reentry tachycardia: a paradoxical effect of adenosine. Pacing Clin Electrophysiol 1993; 16:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern Med 1990; 113:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rinkenberger RL, Prystowsky EN, Heger JJ, et al. Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias. Circulation 1980; 62:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sung RJ, Elser B, McAllister RG Jr. Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. Ann Intern Med 1980; 93:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackman WM, Friday KJ, Fitzgerald DM, et al. Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia. Am J Cardiol 1988; 62:8L.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowey PR, Friehling TD, Marinchak RA. Electrophysiology of beta blockers in supraventricular arrhythmias. Am J Cardiol 1987; 60:32D.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson S, Blanski L, Byrd RC, et al. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group. Am Heart J 1986; 111:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandel WJ, Laks MM, Obayashi K, et al. The Wolff-Parkinson-White syndrome: pharmacologic effects of procaine amide. Am Heart J 1975; 90:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wellens HJ. The wide QRS tachycardia. Ann Intern Med 1986; 104:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang KT, Potts JE, Radbill AE, et al. Permanent junctional reciprocating tachycardia in children: a multicenter experience. Heart Rhythm 2014; 11:1426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorostkar PC, Silka MJ, Morady F, Dick M 2nd. Clinical course of persistent junctional reciprocating tachycardia. J Am Coll Cardiol 1999; 33:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glatter KA, Dorostkar PC, Yang Y, et al. Electrophysiological effects of ibutilide in patients with accessory pathways. Circulation 2001; 104:1933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bianconi L, Boccadamo R, Pappalardo A, et al. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989; 64:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suttorp MJ, Kingma JH, Jessurun ER, et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990; 16:1722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suttorp MJ, Kingma JH, Lie-A-Huen L, Mast EG. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1989; 63:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krahn AD, Klein GJ, Yee R. A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol 2001; 24:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garratt C, Antoniou A, Ward D, Camm AJ. Misuse of verapamil in pre-excited atrial fibrillation. Lancet 1989; 1:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulamhusein S, Ko P, Carruthers SG, Klein GJ. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation 1982; 65:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGovern B, Garan H, Ruskin JN. Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome. Ann Intern Med 1986; 104:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boriani G, Biffi M, Frabetti L, et al. Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. Am Heart J 1996; 131:1214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simonian SM, Lotfipour S, Wall C, Langdorf MI. Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation. Intern Emerg Med 2010; 5:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sellers TD Jr, Bashore TM, Gallagher JJ. Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. Circulation 1977; 56:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackman WM, Wang XZ, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med 1991; 324:1605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuck KH, Schlüter M, Geiger M, et al. Radiofrequency current catheter ablation of accessory atrioventricular pathways. Lancet 1991; 337:1557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calkins H, Sousa J, el-Atassi R, et al. Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test. N Engl J Med 1991; 324:1612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen SA, Tai CT. Ablation of atrioventricular accessory pathways: current technique-state of the art. Pacing Clin Electrophysiol 2001; 24:1795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calkins H, Langberg J, Sousa J, et al. Radiofrequency catheter ablation of accessory atrioventricular connections in 250 patients. Abbreviated therapeutic approach to Wolff-Parkinson-White syndrome. Circulation 1992; 85:1337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol 2000; 23:1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aguinaga L, Primo J, Anguera I, et al. Long-term follow-up in patients with the permanent form of junctional reciprocating tachycardia treated with radiofrequency ablation. Pacing Clin Electrophysiol 1998; 21:2073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez LM, Geller JC, Tse HF, et al. Acute results of transvenous cryoablation of supraventricular tachycardia (atrial fibrillation, atrial flutter, Wolff-Parkinson-White syndrome, atrioventricular nodal reentry tachycardia). J Cardiovasc Electrophysiol 2002; 13:1082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wellens HJ. Should catheter ablation be performed in asymptomatic patients with Wolff-Parkinson-White syndrome? When to perform catheter ablation in asymptomatic patients with a Wolff-Parkinson-White electrocardiogram. Circulation 2005; 112:2201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pappone C, Santinelli V. Should catheter ablation be performed in asymptomatic patients with Wolff-Parkinson-White syndrome? Catheter ablation should be performed in asymptomatic patients with Wolff-Parkinson-White syndrome. Circulation 2005; 112:2207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chevalier P, Cadi F, Scridon A, et al. Prophylactic radiofrequency ablation in asymptomatic patients with Wolff-Parkinson-White is not yet a good strategy: a decision analysis. Circ Arrhythm Electrophysiol 2013; 6:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Todd DM, Klein GJ, Krahn AD, et al. Asymptomatic Wolff-Parkinson-White syndrome: is it time to revisit guidelines? J Am Coll Cardiol 2003; 41:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Etheridge SP, Escudero CA, Blaufox AD, et al. Life-threatening event risk in children with Wolff-Parkinson-White syndrome: a multicenter international study. J Am Coll Cardiol EP 2018; 4:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pappone C, Vicedomini G, Manguso F, et al. Wolff-Parkinson-White syndrome in the era of catheter ablation: insights from a registry study of 2169 patients. Circulation 2014; 130:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pediatric and Congenital Electrophysiology Society (PACES), Heart Rhythm Society (HRS), American College of Cardiology Foundation (ACCF), et al. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). Heart Rhythm 2012; 9:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crossen KJ, Lindsay BD, Cain ME. Reliability of retrograde atrial activation patterns during ventricular pacing for localizing accessory pathways. J Am Coll Cardiol 1987; 9:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackman WM, Friday KJ, Yeung-Lai-Wah JA, et al. New catheter technique for recording left free-wall accessory atrioventricular pathway activation. Identification of pathway fiber orientation. Circulation 1988; 78:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denes P, Wyndham CR, Amat-y-Leon F, et al. Atrial pacing at multiple sites in the Wolff-Parkinson-White syndrome. Br Heart J 1977; 39:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell LB, Mason JW, Scheinman MM, et al. Recordings of basal ventricular preexcitation from electrode catheters in patients with accessory atrioventricular connections. Circulation 1984; 69:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen X, Borggrefe M, Shenasa M, et al. Characteristics of local electrogram predicting successful transcatheter radiofrequency ablation of left-sided accessory pathways. J Am Coll Cardiol 1992; 20:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheinman MM. Catheter ablation for cardiac arrhythmias, personnel, and facilities. North American Society of Pacing and Electrophysiology Ad Hoc Committee on Catheter Ablation. Pacing Clin Electrophysiol 1992; 15:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kay GN, Epstein AE, Dailey SM, Plumb VJ. Role of radiofrequency ablation in the management of supraventricular arrhythmias: experience in 760 consecutive patients. J Cardiovasc Electrophysiol 1993; 4:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calkins H, Yong P, Miller JM, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation 1999; 99:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagres N, Clague JR, Kottkamp H, et al. Radiofrequency catheter ablation of accessory pathways. Outcome and use of antiarrhythmic drugs during follow-up. Eur Heart J 1999; 20:1826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bravo L, Atienza F, Eidelman G, et al. Safety and efficacy of cryoablation vs. radiofrequency ablation of septal accessory pathways: systematic review of the literature and meta-analyses. Europace 2018; 20:1334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Backhoff D, Klehs S, Muller MJ, et al. Long-term follow-up after radiofrequency catheter ablation of accessory atrioventricular pathways in children. J Am Coll Cardiol EP 2018; 4:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen SA, Hsia CP, Chiang CE, et al. Reappraisal of radiofrequency ablation of multiple accessory pathways. Am Heart J 1993; 125:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang JL, Chen SA, Tai CT, et al. Long-term results of radiofrequency catheter ablation in patients with multiple accessory pathways. Am J Cardiol 1996; 78:1375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schweikert RA, Saliba WI, Tomassoni G, et al. Percutaneous pericardial instrumentation for endo-epicardial mapping of previously failed ablations. Circulation 2003; 108:1329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langberg JJ, Calkins H, Kim YN, et al. Recurrence of conduction in accessory atrioventricular connections after initially successful radiofrequency catheter ablation. J Am Coll Cardiol 1992; 19:1588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagres N, Clague JR, Lottkamp H, et al. Impact of radiofrequency catheter ablation of accessory pathways on the frequency of atrial fibrillation during long-term follow-up; high recurrence rate of atrial fibrillation in patients older than 50 years of age. Eur Heart J 2001; 22:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu J, Dole LR. Late complete atrioventricular block complicating radiofrequency catheter ablation of a left posteroseptal accessory pathway. Pacing Clin Electrophysiol 1998; 21:2136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seidl K, Hauer B, Zahn R, Senges J. Unexpected complete AV block following transcatheter ablation of a left posteroseptal accessory pathway. Pacing Clin Electrophysiol 1998; 21:2139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessler DJ, Pirwitz MJ, Horton RP, et al. Intracardiac shunts resulting from transseptal catheterization for ablation of accessory pathways in otherwise normal hearts. Am J Cardiol 1998; 82:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitchet A, Turkie W, Fitzpatrick AP. Transeptal approach to ablation of left-sided arrhythmias does not lead to persisting interatrial shunt: a transesophageal echocardiographic study. Pacing Clin Electrophysiol 1998; 21:2070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kocovic DZ, Harada T, Shea JB, et al. Alterations of heart rate and of heart rate variability after radiofrequency catheter ablation of supraventricular tachycardia. Delineation of parasympathetic pathways in the human heart. Circulation 1993; 88:1671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Psychari SN, Theodorakis GN, Koutelou M, et al. Cardiac denervation after radiofrequency ablation of supraventricular tachycardias. Am J Cardiol 1998; 81:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamdan MH, Page RL, Wasmund SL, et al. Selective parasympathetic denervation following posteroseptal ablation for either atrioventricular nodal reentrant tachycardia or accessory pathways. Am J Cardiol 2000; 85:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox JL, Gallagher JJ, Cain ME. Experience with 118 consecutive patients undergoing operation for the Wolff-Parkinson-White syndrome. J Thorac Cardiovasc Surg 1985; 90:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrie GM, Lin HT, Wyndham CR, DeBakey ME. Surgical treatment of supraventricular arrhythmias. Results in 67 patients. Ann Surg 1987; 205:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson DC, Nunn GR, Richards DA, et al. Surgical therapy for supraventricular tachycardia, a potentially curable disorder. J Thorac Cardiovasc Surg 1987; 93:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holman WL, Kay GN, Plumb VJ, Epstein AE. Operative results after unsuccessful radiofrequency ablation for Wolff-Parkinson-White syndrome. Am J Cardiol 1992; 70:1490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SS, Lal R, Ruffy R. Treatment of paroxysmal reentrant supraventricular tachycardia with flecainide acetate. Am J Cardiol 1986; 58:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward DE, Jones S, Shinebourne EA. Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome. Am J Cardiol 1986; 57:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ludmer PL, McGowan NE, Antman EM, Friedman PL. Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. J Am Coll Cardiol 1987; 9:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musto B, D'Onofrio A, Cavallaro C, Musto A. Electrophysiological effects and clinical efficacy of propafenone in children with recurrent paroxysmal supraventricular tachycardia. Circulation 1988; 78:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenbaum MB, Chiale PA, Ryba D, Elizari MV. Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. Am J Cardiol 1974; 34:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wellens HJ, Lie KI, Bär FW, et al. Effect of amiodarone in the Wolff-Parkinson-White syndrome. Am J Cardiol 1976; 38:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feld GK, Nademanee K, Weiss J, et al. Electrophysiologic basis for the suppression by amiodarone of orthodromic supraventricular tachycardias complicating pre-excitation syndromes. J Am Coll Cardiol 1984; 3:1298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chouty F, Coumel P. Oral flecainide for prophylaxis of paroxysmal atrial fibrillation. Am J Cardiol 1988; 62:35D.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antman EM, Beamer AD, Cantillon C, et al. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988; 12:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kappenberger LJ, Fromer MA, Steinbrunn W, Shenasa M. Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation. Am J Cardiol 1984; 54:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feld GK, Nademanee K, Stevenson W, et al. Clinical and electrophysiologic effects of amiodarone in patients with atrial fibrillation complicating the Wolff-Parkinson-White syndrome. Am Heart J 1988; 115:102.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 996 Version 50.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26399663" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31504425" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385681" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Impact of a modified Valsalva manoeuvre in the termination of paroxysmal supraventricular tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2664879" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The cardiac effects of adenosine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4019929" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6640877" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7847646" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Proarrhythmia in patients with the Wolff-Parkinson-White syndrome after standard doses of intravenous adenosine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7681179" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Provocation of atrioventricular reentry tachycardia: a paradoxical effect of adenosine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2193560" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7418184" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7212475" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3059792" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2888299" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Electrophysiology of beta blockers in supraventricular arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2868645" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1199922" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The Wolff-Parkinson-White syndrome: pharmacologic effects of procaine amide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3593468" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The wide QRS tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24769425" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Permanent junctional reciprocating tachycardia in children: a multicenter experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9973016" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Clinical course of persistent junctional reciprocating tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24682348" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11602497" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Electrophysiological effects of ibutilide in patients with accessory pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2667304" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2123909" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2493733" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11523612" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2563516" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Misuse of verapamil in pre-excited atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7053894" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3706931" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8644602" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20437113" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/872319" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2030716" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1675706" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Radiofrequency current catheter ablation of accessory atrioventricular pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2030717" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11817815" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Ablation of atrioventricular accessory pathways: current technique-state of the art.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1555278" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Radiofrequency catheter ablation of accessory atrioventricular connections in 250 patients. Abbreviated therapeutic approach to Wolff-Parkinson-White syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10879389" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The 1998 NASPE prospective catheter ablation registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9826859" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Long-term follow-up in patients with the permanent form of junctional reciprocating tachycardia treated with radiofrequency ablation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12475096" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Acute results of transvenous cryoablation of supraventricular tachycardia (atrial fibrillation, atrial flutter, Wolff-Parkinson-White syndrome, atrioventricular nodal reentry tachycardia).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16203931" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Should catheter ablation be performed in asymptomatic patients with Wolff-Parkinson-White syndrome? When to perform catheter ablation in asymptomatic patients with a Wolff-Parkinson-White electrocardiogram.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16208793" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Should catheter ablation be performed in asymptomatic patients with Wolff-Parkinson-White syndrome? Catheter ablation should be performed in asymptomatic patients with Wolff-Parkinson-White syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23362302" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prophylactic radiofrequency ablation in asymptomatic patients with Wolff-Parkinson-White is not yet a good strategy: a decision analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12535817" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Asymptomatic Wolff-Parkinson-White syndrome: is it time to revisit guidelines?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Life-threatening event risk in children with Wolff-Parkinson-White syndrome: a multicenter international study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25052405" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Wolff-Parkinson-White syndrome in the era of catheter ablation: insights from a registry study of 2169 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22579340" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3584720" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Reliability of retrograde atrial activation patterns during ventricular pacing for localizing accessory pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3409499" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : New catheter technique for recording left free-wall accessory atrioventricular pathway activation. Identification of pathway fiber orientation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/861093" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Atrial pacing at multiple sites in the Wolff-Parkinson-White syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6690096" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Recordings of basal ventricular preexcitation from electrode catheters in patients with accessory atrioventricular connections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1512346" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Characteristics of local electrogram predicting successful transcatheter radiofrequency ablation of left-sided accessory pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1382271" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Catheter ablation for cardiac arrhythmias, personnel, and facilities. North American Society of Pacing and Electrophysiology Ad Hoc Committee on Catheter Ablation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8269306" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Role of radiofrequency ablation in the management of supraventricular arrhythmias: experience in 760 consecutive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9892593" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10581141" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Radiofrequency catheter ablation of accessory pathways. Outcome and use of antiarrhythmic drugs during follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29036312" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Safety and efficacy of cryoablation vs. radiofrequency ablation of septal accessory pathways: systematic review of the literature and meta-analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Long-term follow-up after radiofrequency catheter ablation of accessory atrioventricular pathways in children
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8438705" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Reappraisal of radiofrequency ablation of multiple accessory pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8970409" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Long-term results of radiofrequency catheter ablation in patients with multiple accessory pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12952851" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Percutaneous pericardial instrumentation for endo-epicardial mapping of previously failed ablations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1593055" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Recurrence of conduction in accessory atrioventricular connections after initially successful radiofrequency catheter ablation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11207084" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Impact of radiofrequency catheter ablation of accessory pathways on the frequency of atrial fibrillation during long-term follow-up; high recurrence rate of atrial fibrillation in patients older than 50 years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9826868" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Late complete atrioventricular block complicating radiofrequency catheter ablation of a left posteroseptal accessory pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9826869" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Unexpected complete AV block following transcatheter ablation of a left posteroseptal accessory pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9708675" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Intracardiac shunts resulting from transseptal catheterization for ablation of accessory pathways in otherwise normal hearts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9826858" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Transeptal approach to ablation of left-sided arrhythmias does not lead to persisting interatrial shunt: a transesophageal echocardiographic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8403312" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Alterations of heart rate and of heart rate variability after radiofrequency catheter ablation of supraventricular tachycardia. Delineation of parasympathetic pathways in the human heart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9527082" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Cardiac denervation after radiofrequency ablation of supraventricular tachycardias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10758931" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Selective parasympathetic denervation following posteroseptal ablation for either atrioventricular nodal reentrant tachycardia or accessory pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4046618" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Experience with 118 consecutive patients undergoing operation for the Wolff-Parkinson-White syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3592813" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Surgical treatment of supraventricular arrhythmias. Results in 67 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3573801" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Surgical therapy for supraventricular tachycardia, a potentially curable disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1442625" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Operative results after unsuccessful radiofrequency ablation for Wolff-Parkinson-White syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3728336" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Treatment of paroxysmal reentrant supraventricular tachycardia with flecainide acetate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3962866" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3294970" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3168194" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Electrophysiological effects and clinical efficacy of propafenone in children with recurrent paroxysmal supraventricular tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1900101" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4843156" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/952262" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Effect of amiodarone in the Wolff-Parkinson-White syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6707383" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Electrophysiologic basis for the suppression by amiodarone of orthodromic supraventricular tachycardias complicating pre-excitation syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3136633" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Oral flecainide for prophylaxis of paroxysmal atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3417972" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6465013" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3336964" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Clinical and electrophysiologic effects of amiodarone in patients with atrial fibrillation complicating the Wolff-Parkinson-White syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
